IndicationsLarotrectinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
- Harbor a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation;
- Are metastatic or where surgical resection is likely to result in severe morbidity; and
- Have no satisfactory alternative treatment options or have progressed following treatment.
Dosage and Administration
- Select patients for treatment with larotrectinib based on the presence of an NTRK gene fusion.
- Recommended Dose:
- For adults and pediatric patients with body surface area (BSA) ≥ 1.0 m²: 100 mg orally twice daily.
- For pediatric patients with body surface area (BSA) < 1.0 m²: 100 mg/m² orally twice daily.
Reviews
There are no reviews yet.